(Q34655437)

3 August 2017

The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer (English)

1 reference

3 August 2017

1 reference

1 reference

Stephen K Chia

1

1 reference

3 August 2017

Caroline H Speers

2

1 reference

3 August 2017

Yulia D'yachkova

3

1 reference

3 August 2017

Anna Kang

4

1 reference

3 August 2017

Suzanne Malfair-Taylor

5

1 reference

3 August 2017

Jeff Barnett

6

1 reference

3 August 2017

Andy Coldman

7

1 reference

3 August 2017

Karen A Gelmon

8

1 reference

3 August 2017

Susan E O'reilly

9

1 reference

3 August 2017

Ivo A Olivotto

10

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

3 August 2017

1 reference

3 August 2017

110

1 reference

3 August 2017

5

1 reference

3 August 2017

973-979

1 reference

Recent trends in U.S. breast cancer incidence, survival, and mortality rates

3 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22867

7 January 2021

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22867

7 January 2021

Treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22867

7 January 2021

UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22867

7 January 2021

Effect of screening and adjuvant therapy on mortality from breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22867

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22867

7 January 2021

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22867

7 January 2021

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22867

7 January 2021

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22867

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22867

7 January 2021

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22867

7 January 2021

Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22867

7 January 2021

Is breast cancer survival improving?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22867

7 January 2021

American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22867

7 January 2021

Identifiers

DOI

10.1002/CNCR.22867

1 reference

3 August 2017

1 reference